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(57) ABSTRACT 
A method and system for detecting the presence of restric-
tion to expired airflow in humans or animals by analyzing 
the expired capnogram and oxygram, as well as the geo-
metric analysis of the real-time plot of the waveform that 
depicts the instantaneous ratio of C02 to 0 2 (the carboxy-
gram ratio). Airway obstructions causes an increase in the 
Q-angle between the slope of phase 11 and slope of phase III 
in the expired carboxygram. The diagnostic accuracy of the 
detection of airways obstruction is further enhanced by 
measuring the ratio of time spent in exhalation (Te) versus 
inhalation (Ti). The system uses the combination of an 
increased carboxygram Q-angle, and a prolonged Te/Ti to 
detect presence of airways obstruction. 
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SYSTEM AND METHOD FOR DETERMINING 
AIRWAY OBSTRUCTION 
BACKGROUND OF THE INVENTION 
[0001] 1. Field of Invention 
[0002] The present invention relates to the diagnosis of 
airways obstruction and, more specifically, to a system and 
method for determining the severity and cause of breathing 
difficulties in respiratory patients. 
[0003] 2. Description of Prior Art 
[0004] Obstruction of the breathing passages within the 
lungs represents a common medical condition. Approxi-
mately 20 million Americans have the condition of bronchial 
asthma, and another 7 million have the condition of chronic 
obstructive pulmonary disease (COPD). Several million 
other Americans have intermittent spells of difficulty breath-
ing caused by reversible airways hyperreactivity. While the 
underlying causes of all of these conditions differ, they all 
produce restriction to airflow during exhalation. 
[0005] In human and veterinary medicine, clinicians mea-
sure the severity of airways restriction to guide treatment 
decisions. In human medicine, the severity of restriction is 
quantified by currently measuring the maximal rate of 
airflow during a forced exhalation. The most common 
embodiments of this method include the forced exhalation 
volume during one second (FEV1 ) and the peak flow mea-
surement. The measurement of peak exhaled airflow 
requires the patient to hold a mouthpiece with an airtight 
seal, and to exhale rapidly and forcefully as possible. This 
process inherently incorporates an unquantifiable variable of 
patient cooperation. Accordingly, abnormally low readings 
are often unreliable, especially in acutely ill patients. 
OBJECTS AND ADVANTAGES 
[0006] It is a principal object and advantage of the present 
invention to provide a system and method for determining 
the presence and severity of airways obstruction. 
[0007] It is a further object and advantage of the present 
invention to provide a system and method for measuring the 
presence and severity of airways obstruction that is less 
effort-dependent. 
[0008] It is an additional object and advantage of the 
present invention to provide a system and method for 
measuring the presence and severity of airways obstruction 
that is more reliable. 
[0009] It is also an object and advantage of the present 
invention to provide a system and method for measuring the 
presence and severity of airways obstruction that is easier to 
reproduce in home and clinical settings. 
[0010] Other objects and advantages of the present inven-
tion will in part be obvious, and in part appear hereinafter. 
SUMMARY OF THE INVENTION 
[0011] The present invention comprises a system and 
method for simultaneously measuring the pC02 and p02 of 
a patients and plotting of the ratio ofCOi02 instantaneously 
(hereinafter referred to as the "carboxygram") to determine 
whether the shape of the carboxygram has been deformed in 
manner indicative of airways obstruction. The effect of an 
1 
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airways obstruction on the expired oxygram and carboxy-
grams, i.e., the tracing of the partial pressure of expired 
oxygen (p02 ) and the partial pressure of expired carbon 
dioxide (pC02 ), will deform in a predictable manner. The 
system and method of the present invention measures partial 
pressures of expired oxygen and carbon dioxide and then 
determines the effect of airways obstruction on both the 
capnogram and the oxygram to diagnose and/or predict the 
presence an airways obstruction in a patient. The system and 
method of the present invention also uses the delay in the 
time period required for expiration (Te) compared with 
inspiration (Ti) to diagnose airways obstruction. Based on 
the results of the measurements taken according to the 
present invention, a preliminary diagnosis may be reached 
by comparing the measured results to normal and afflicted 
populations. 
BRIEF DESCRIPTION OF THE DRAWINGS 
[0012] The present invention will be more fully under-
stood and appreciated by reading the following Detailed 
Description in conjunction with the accompanying draw-
ings, in which: 
[0013] FIG. 1 is a graph of a capnogram according to the 
present invention. 
[0014] FIG. 2 is a graph of a capnogram according to the 
present invention. 
[0015] FIG. 3 is a graph of a capnogram according to the 
present invention. 
[0016] FIG. 4 is a graph of a capnogram according to the 
present invention. 
[0017] FIG. 5 is a schematic of a system according to the 
present invention. 
[0018] FIG. 6 is a schematic of another embodiment 
according to the present invention. 
[0019] FIG. 7 is a schematic of a further embodiment 
according to the present invention. 
[0020] FIG. 8 is an example of a visual display of a system 
according to the present invention. 
[0021] FIG. 9 is an example of a visual display of a system 
according to the present invention. 
[0022] FIG. 10 is an example of a visual display of a 
system according to the present invention. 
[0023] FIG. 11 is an example of a visual display of a 
system according to the present invention. 
[0024] FIG. 12 is an example of a visual display of a 
system according to the present invention. 
[0025] FIG. 13 is an example of a visual display of a 
system according to the present invention. 
[0026] FIG. 14 is a graphical comparison of measurements 
according to the present invention. 
[0027] FIG. 15 is a graph of a carboxygram according to 
the present invention. 
[0028] FIG. 16 is a graph of a carboxygram according to 
the present invention. 
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[0029] FIG. 17 is a graph of the results of a calculation 
according to the present invention. 
[0030] FIG. 18 is a graph of the results of a calculation 
according to the present invention. 
DETAILED DESCRIPTION 
[0031] Referring now to the drawings, wherein like 
numerals refer to like parts throughout, there is seen in 
FIGS. 1 and 2 two graphs depicting the measurement of 
expired PC02 (capnograms) as a function of time and 
volume, respectively, in a normal patient. A patient having 
an acute airways obstruction will demonstrate altered geom-
etry of these curves, as seen in FIGS. 3 and 4. The two 
components of the expired capnogram that are affected by 
airways obstruction are the slopes of the plotted curves in the 
areas designated as Phase II and Phase III. Phase II repre-
sents the volume of breath that empties the conducting 
airways of the lungs, including the trachea and bronchioles. 
This volume is collectively termed the airway or anatomic 
deadspace portion of expired breath. Phase III depicts the 
partial pressure of C02 (pC02) contained within gas expired 
from the alveoli. As seen in FIGS. 1 and 2, the slope (or first 
derivative) of Phase II is generally high in normal patients. 
The high slope depicts the normal sharp and rapid transition 
that occurs as the conducting airways empty their content of 
ambient air, and begin to expire alveolar gas which was 
equilibrated with the C02 content in mixed venous blood. 
Conversely, the slope of Phase III is flat, representing a 
relatively homogenous partial pressure of C02 within alveo-
lar gas. 
[0032] Referring to FIGS. 3 and 4, the sharp and rapid 
transition described in phase II becomes blunted in patients 
with disease-induced restriction to expired airway flow. 
With disease, a proportion of airways remain patent, while 
a proportion is partially or totally occluded. During exhala-
tion, the patent airways empty first, and begin to transition 
to the alveolar portion of the breath, while in the partially 
occluded airways the transition to the alveolar phase is 
delayed. As a result, alveolar gas from the patent airways 
mixes with the anatomic gas from the diseased airways, 
contributing to an increased amount ofC02 in Phase II of the 
curve, causing its slope to decrease. This non-homogenous 
emptying also affects Phase II, because the restricted air-
ways require variable time periods to empty. This variable 
time requirement causes two effects that contribute to the 
increased slope of Phase III. The first is the continued 
heterogenous mixing of conducting gas with alveolar gas, 
and the second is an increase in the time needed for the 
alveolar gas to equilibrate with the mixed venous blood in 
the most diseased airways, resulting in higher pC02 in the 
expired gas that is the most delayed. 
[0033] Referring to FIG. 5, the present invention includes 
a device 10 for measuring the volume air and PC02 and p02 
expired from a patient. Device 10 comprises a patient 
mouthpiece 12 connected in fluid communication to a 
breathing tube 14 having an open end 16 through which air 
may be exhaled or inhaled by a patient. Device 10 further 
comprises a airflow transducer or pneumotach 18 for mea-
suring expired flow rate, a fast-response sensor 20 for 
measuring C02 and a fast response sensor 22 for measuring 
02, all of which are situated in series and in-line with 
breathing tube 14 for simultaneously measuring the flow, 
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carbon dioxide, and oxygen levels of air inhaled and exhaled 
by a patient through the tube. Pneumotach 18, carbon 
dioxide sensor 20, and oxygen sensor 22 are electrically 
interconnected to a microprocessor 24 having an analog-to-
digital converter for sampling the electrical outputs of the 
measuring elements. Device 10 further comprises a pulse 
oximetry module 26 electrically interconnected to micro-
processor 24. Microprocessor 24 is electrically intercon-
nected to a screen 28 for visually displaying various calcu-
lations, measurements, and graphical representations of the 
measured data according to the present invention. 
[0034] Microprocessor 24 should be programmed to pro-
vide a Ti/Te ratio and calculate the slope of graph of the 
C02/02 ratios during Phase II and Phase III of the running 
carboxygram plot. Microprocessor 24 may comprise a 
MP! 00 system available from Biopac Systems, Inc, of Santa 
Barbara, Calif. Microprocessor 24 must determine the run-
ning average of Ti and Te and compute the average Ti/Te 
based upon the mean value obtained from breaths obtained 
during approximately a 30 second period of breathing. This 
value can be displayed as "summary data" on screen 28. 
Screen 28 can also provide reference intervals for Ti/Te, as 
measured in healthy subjects and patients with various 
disease states, including diseases that cause airway obstruc-
tion, and pulmonary embolism to assist in clinical diagnosis. 
For example, patients diagnosed with pulmonary embolism 
have a mean Ti/Te of 0.72±0.13, patients having had pul-
monary embolism ruled out have a mean Ti/Te of0.71±0.26, 
healthy patients have a Ti/Te of0.75±0.15, and patient with 
acute exacerbation of bronchial asthma have a Ti/Te of 
0.45±0.35. 
[0035] Microprocessor 24 should also be progrannned to 
normalize the signals obtained for all sensors to correct for 
differential sensor speed. For example, in general, oxygen 
sensing devices require more time to respond to a change in 
oxygen partial pressure, compared with the ability of an 
infrared absorption detection system to respond to a change 
in partial pressure of carbon dioxide. If at a given flow rate, 
an oxygen sensor has a delay of 250 ms, and a carbon 
dioxide sensor which has a delay of 50 ms (both sensors 
operating at the same frequency), then microprocessor 24 
must match any given co2 data point with an 02 data point 
that arrives 200 ms later. Microprocessor 24 must execute 
this delay correction according to differential sensor delays 
as a function of flow rate. 
[0036] Microprocessor 24 should also be progrannned to 
determine the slopes of Phase II and III of the carboxygrams 
obtained from the two deep exhalations and the average 
slopes obtained during 30 seconds of tidal breathing. These 
slopes can be computed with two X-axes; time and volume. 
To facilitate clinician understanding, microprocessor 24 
should be progrannned to report the overlay of several 
breaths obtained during a 30 second period of tidal breath-
ing, plotting the C02/02 ratio as a function of either time or 
volume. 
[0037] Carbon dioxide and oxygen partial pressures may 
be quantified in real-time by sensors 20 and 22 that are 
capable of performing infrared absorptiometry and para-
magnetic deviation, respectively. An acceptable absorptiom-
eter sensor 20 is Model No. C02100C Carbon Dioxide 
Measurement Model available from Biopac Systems, and an 
acceptable paramagnetic sensor 22 is Model No. 02100C 
US 2007/0123792 Al 
Oxygen Measurement Module, also available from Biopac 
Systems. Sensors 20 and 22 should be calibrated against two 
dry reference gases (0% C02/21% 0 2 and 7.5% C0i12% 
0 2 ) before sampling from a patient, and the readings of the 
reference gases should be repeated immediately after data is 
collected from each patient to evaluate for calibration sta-
bility. 
[0038] Airflow transducer 18 should be tested against a 
volumetric calibration syringe, such as Model No. AFT 26 
2L, available from Biopac Systems, immediately before and 
after each patient. Airflow, expired volume, continuous 
tracings of expired C02 and 0 2 are recorded at body tem-
perature and saturated with water and at ambient pressure 
(BTSP). The data may be archived digitally after analog-
to-digital conversion by using commercially available soft-
ware, such as theACKlOOW AcqKnowledge software avail-
able from Biopac Systems. 
[0039] Mouthpiece 12 into which the patient breathes can 
comprise a standard plastic duckbill mouthpiece where the 
patient forms a seal against the device, a rubber bit-block 
device that the patient puts into his or her mouth, or a face 
mask as described next. Examples of such devices may be 
commonly found in conventional respiratory therapy supply 
carts, such as a Hudson RCI plastic duckbill, a rubber Kraton 
7/s" internal diameter, reusable mouthpiece (Catalog No. 
1645 of AM Systems, Inc. of Carlsborg, Wash.), or a Hans 
Rudolph series 7600 full face mask with three-way valve to 
allow measurement of the partial pressure of therapeutic 
oxygen and the partial pressure of oxygen in expired breath. 
The latter configuration is especially desirable in a patient 
with severe respiratory distress to allow delivery of exog-
enous oxygen and to measure the inspired p02 and expired 
p02 . Other full face masks are equally adaptable for use in 
connection with the present invention, including the dispos-
able Mirage mask available from ResMed Ltd. of Sydney 
NSW, Australia. 
[0040] Referring to FIG. 6, mouthpiece 12 may be a 
disposable assembly of a first portion 34 coupled with a 
dehumidifying chamber 36. In an alternative embodiment, 
disposable portion 34 includes a portion of02 sensor 22. For 
either embodiment, the various 0 2 , C02 and flow sensors, 
are preferably are lightweight ( <100 grams in total), com-
pact, and have fast response times ( <50 ms). In addition, the 
deadspace volume should be not more than 15 mL, and the 
inner diameter should be approximately 13 mm. Each end of 
device 10 should further be adaptable to couple with an 
endotracheal tube to allow connection within a ventilatory 
circuit for use with a patient receiving mechanical ventila-
tion. 
[0041] Oxygen sensor 22 can operate using known prin-
ciples of detection such as galvanic, paramagnetic, mass- or 
laser-spectrometry, calorimetry, or fluorescent detection. 
Commercially available oxygen sensors include the electro-
chemical sensor manufactured by Sensors for Medicine and 
Science, Inc. of Germantown, Md. (http://www.s4ms.com) 
or the fluorescent sensor known as the SentrOxy OEM-PFT 
available through Sentronic GmbH (http://www.sentronic-
.net). 
[0042] Carbon dioxide sensor 20 can operate using either 
non-dispersive infrared absorption, mass- or laser-spectro-
metric detection. A commercially available C02 sensor suit-
able to this purpose is the Capnostat mainstream etC02 
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infrared sensor available from Respironics, Wallingford, 
Conn. Multiple methods can be used to detect mainstream 
flow, including those that employ Bernoulli's equation based 
upon pressure differential across an orifice, those that use 
thermal differential methods, and those that use piezieolec-
tric principles. 
[0043] Flow sensor 18 should have a detection range from 
zero to a minimum of 15 L/Sec with an accuracy of 
approximately ±3%. A commercially available device that 
meets these tolerances is the Vmax mass flow sensor avail-
able from SensorMedics, Yorba Linda, Calif. Flow data can 
then be integrated to yield volume. Although these particular 
measuring technologies represent an acceptable means for 
detecting 0 2 , C02 and flow, it should be recognized by one 
of skill in the art that other technologies could be employed 
to achieve the same objective. 
[0044] Each sensor 18, 20, and 22 produces an electrical 
current that is digitized by microprocessor 24 prior to 
analysis by using an analog-to-digital converter with suffi-
cient bandwidth and a sampling rate of aproximately 75 Hz 
to 300 kHz. Microprocessor 24 must perform basic func-
tions for measuring Ti and Te and computing the average 
Ti/Te for a present period of breath collection (e.g., one 
minute). 
[0045] The configuration of sensors 18, 20, and 22 can 
affect the device performance. In the preferred embodiment, 
the flow sensor 12, C02 sensor 20, and 0 2 sensor 22 are 
positioned in a mainstream fashion to measure each param-
eter directly within the path of exhaled breath, as seen in 
FIGS. 5 and 6. As an alternative, measurement of C02 and 
0 2 to occur may be taken in sidestream by transferring 
sample air via vacuum tubing to the applicable sensors. This 
embodiment, while theoretically feasible, is less desirable 
due to the difficulty of compensating for errors introduced by 
the variables such as the rate of vacuum aspiration, tubing 
length, diameter, condensation, tubing kinking, and other 
problems. 
[0046] According to the method of the present invention, 
device 10 is provided to a patient for measurement of the 
various gases. The patient should breathe ambient air for at 
least two minutes prior to taking measurements with device 
10. Breaths are collected from a patient seated in semi-
Fowler's position and wearing nose clips. Patients should 
deliver a sharp, rapid, deep exhalation to a maximum 
endpoint, starting from a midpoint of tidal breathing (i.e., 
not delivered after a sigh inspiration), followed by a few 
normal breaths, and then a thirty second period of tidal 
breathing. All measurements may be taken during this breath 
collection interval. This sequence should be repeated twice 
more, yielding three deep exhalations and three 30-second 
samples of tidal breathing. 
[0047] Cooperative patients can hold device 10 in their 
hands, and breathe into mouthpiece 12. The patient should 
first provide a deep exhalation, and then breathe for 30 
seconds, followed by a second deep exhalation. All mea-
surements may be taken during this breath collection inter-
val. For obtunded patients or those with severe distress, 
breaths can be collected using a face mask connected in fluid 
series to a T-piece with valves oriented to allow oxygen to 
be delivered such that both the inspiratory and expiratory 
p0
2 
can be measured. 
[0048] FIGS. 8, 9, and 10 depict measurements obtained 
during spontaneous breathing from a healthy control subject, 
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a subject with airway obstruction from bronchial asthma, 
and a subject with pulmonary embolism, respectively, 
according to the procedures detailed above. FIGS. 8, 9, and 
10 demonstrate that the Te is generally prolonged relative to 
Ti in the patient with bronchial asthma. FIGS. 8, 9, and 10 
also show that the Te and Ti may be deduced from the 
capnogram, but it should be obvious that Te and Ti could be 
estimated from other measured or calculated parameters 
including expired flow, volume, p02 , the ratio of pCOip02 , 
or pN2 . 
[0049] FIGS. 8, 9, and 10 further illustrate that the expi-
ratory capnograms, oxygrams and the carboxygrams differ 
between normal patients, patients with asthma, and patients 
with pulmonary embolism. In particular, normal patients 
have capnograms and carboxygrams with a larger area under 
each curve, but with fewer breaths per unit of time compared 
with either patients with asthma or patients with pulmonary 
embolism. Patients with pulmonary embolism demonstrate 
capnograms and carboxygrams with particularly small areas. 
[0050] There is seen in FIGS. 11, 12, and 13, plots of a 
breath obtained from a single deep exhalation illustrate the 
effect of an airways obstruction on the expired oxygram and 
carboxygram. FIG. 11 was obtained from a normal subject, 
FIG. 12 from a patient with acute asthma, and FIG. 13 from 
a patient with pulmonary embolism. The arrows drawn 
under the nadir asymptote of the boxed-in oxygram for each 
patient represent a visual estimation of the first derivative of 
this asymptote. This portion of the oxygram corresponds to 
Phase III of the capnogram. It can be seen that the slope of 
the Phase III portion of the oxygram increases in a patient 
with asthma. 
[0051] In FIGS. 11, 12, and 13, the fourth tracing illus-
trates the carboxygram (instantaneous ratio ofC02 :02). The 
dotted arrows in FIGS. 11 and 12 are drawn approximately 
tangent to the Phase III component, and illustrate an increase 
in slope in the patient with asthma. Similarly, the slope of 
Phase II is decreased only in the patient with asthma. 
[0052] Referring to FIG. 14, three representative carboxy-
grams from FIGS. 11, 12, and 13 are reproduced for com-
parison and analysis. The Q-angle is denoted by 01 for a 
normal subject, 82 for the patient a bronchial asthma, and 83 
for a patient with pulmonary embolism. The graphs show 
that 82 is widened more than 81or83. The measurement of 
these angles in normal subjects is a mean of 110±8 degrees, 
in patients with asthma is a mean of 132±4 degrees, and in 
patients with PE is a mean of 105±5 degrees. In general, 
patients with clinically significant airways restriction dem-
onstrate a 8 greater than 120°. 
[0053] Inspiratory time, Ti can be defined by the resulting 
capnogram, the oxygram, or the flow data. Using flow 
curves to define the start and stop of Ti and Te provides a 
theoretical advantage of estimating the start of exhalation 
during the initial emptying phase of the airways and before 
C02 increases and 0 2 decreases. On the other hand, C02 
increases and 0 2 decreases during exhalation only after the 
airway deadspace (100-300 mL) has mostly evacuated and 
the subject begins to empty the alveoli. Typically, dual 
thresholds in flow are used to mark the start of exhalation 
and inhalation, including a >±10 Umin rate of flow change, 
and greater than 25 mL total volume change in an adult. 
Similarly, the Ti and Te can be marked by the true upslope 
of the C02 curve (based upon a trigger consisting of an 
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absolute C02 value >2.0 mm Hg and a + 10 mm Hg C02/sec 
rate of rise) and return to the baseline, using similar values. 
Likewise, thresholds can be set on the oxygram upslope and 
downslope to mark the start of exhalation and inhalation, 
respectively. 
[0054] FIGS. 15 and 16 schematically demonstrate three 
different carboxygrams from three breaths as three different 
lines; one with short dashes, a second with long dashes and 
a third via a solid line. The dashed straight lines represent the 
average value of the vectors defined by Phases II and III for 
each of the three carboxygrams. Microprocessor 24 may also 
produce an output to screen 28 to display that demonstrate 
the best-fit slope of phase II and phase III and that report the 
mean 8. These values are also exported in numeric format 
(with mean and variance data as needed) to screen 28. 
Screen 28 then reports the values of each variable measured 
in previously studied cohorts of normal subjects and patients 
with airway restriction and patients with pulmonary embo-
lism. 
[0055] In an alternative embodiment, microprocessor 24 is 
programmed to instantly differentiate the change in the ratio 
of C02/02 as a function of time or volume according to the 
equations, where t=time and V =expired breath volume: 
F(x)~d(C0i02)/dt 
F(x)~d(C02/02)/dV 
[0056] FIGS. 17 and 18 illustrate an output according to 
this embodiment. In this case, the maximum positive deflec-
tion A represents the slope of phase II, and the mean value 
of the descending flat portion B represents the slope of phase 
III. The difference C, obtained by subtracting B from A, 
varies directly in proportion to 8. The numeric values of A, 
B and their difference C may be exported and shown on 
screen 28 as a summary page or depicted relative to previ-
ously measured data in normal and diseased subjects. 
[0057] Although the present invention focuses on the 
analysis of a carboxygram, it should be obvious to those 
skilled in the art that other gases could be used to measure 
the severity of airway restriction, including a plot of pN 2 or 
plots of ratios containing pN2 as a numerator or denomina-
tor. Likewise, the device could be configured to detect 
similar changes in slope of the partial pressure of exog-
enously inhaled and poorly absorbed gases, including inert 
gases such as helium. 
What is claimed is: 
1. A system for diagnosing the presence of abnormal 
respiratory function, comprising: 'a breathing tube through 
which a subject may take one or more breaths over a 
predetermined time period; 
a flow meter connected to said tube; 
an oxygen meter connecter to said tube; 
a carbon dioxide meter connected to said tube; and 
a microprocessor connected to said flow meter, said 
oxygen meter, said carbon dioxide meter, and said 
pulse oximeter, wherein said microprocessor is pro-
grammed to calculate the ratio of carbon dioxide to 
oxygen in said breaths in real-time. 
2. The system of claim 1, wherein the microprocessor is 
programmed to correct for the differential response rates of 
carbon dioxide meters. 
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3. The system of claim 1, further comprising a display 
screen connected to said microprocessor. 
4. The system of claim 3, wherein said display screen 
displays a plot of the ratios of the carbon dioxide to oxygen 
in real-time over said predetermined time period. 
5. The system of claim 4, wherein said display screen 
displays the plot of the ratios of carbon dioxide to oxygen as 
a smoothed line. 
6. The system of claim 3, wherein said display screen 
displays a plot of the ratios of the partial pressures of carbon 
dioxide to oxygen in real-time over a predetermined time 
period in combination with previously measured ratios of 
partial pressures of carbon dioxide to oxygen in normal and 
afflicted populations. 
7. The system of claim 3, wherein said microprocessor is 
programmed to calculate a running average inspiration time 
and expiration time over a predetermined time period. 
8. The system of claim 7, wherein said display screen 
displays a plot of the running average inspiration time and 
expiration time over a predetermined time period. 
9. The system of claim 8, wherein said display screen 
displays the plot of the running average inspiration time and 
expiration time over a predetermined time period as a 
smooth line. 
10. The system of claim 8, wherein said display screen 
displays a plot of the running average inspiration time and 
expiration time over a predetermined time period in com-
bination with previously measured average inspiration time 
and expiration time in normal and afflicted populations. 
11. The system of claim 3, wherein said microprocessor is 
programmed to calculate the straight line slope of a first 
predetermined portion of a plot of the ratio of carbon dioxide 
to oxygen. 
12. The system of claim 11, wherein said microprocessor 
is programmed to calculate the straight line slope of a second 
predetermined portion of a plot of the ratio of carbon dioxide 
to oxygen. 
13. The system of claim 12, wherein said microprocessor 
is programmed to determine the widest angle formed by the 
intersection of the straight line slope of the first predeter-
mined portion and the straight line slope of the second 
predetermined portion. 
14. The system of claim 3, wherein said microprocessor 
is programmed to calculate the first derivative of a first 
predetermined portion of a plot of the ratio of carbon dioxide 
to oxygen. 
15. The system of claim 14, wherein said microprocessor 
is programmed to calculate the first derivative of a second 
predetermined portion of a plot of the ratio of carbon dioxide 
to oxygen. 
16. The system of claim 15, wherein said microprocessor 
is programmed to calculate the difference in the maximum 
first derivative of the first predetermined portion minus the 
maximum first derivative of the second predetermined por-
tion. 
17. The system of claim 4, further including a database 
containing previously measured ratios of carbon dioxide to 
oxygen in normal and afflicted subjects interconnected to 
said microprocessor. 
18. The system of claim 17, wherein said display screen 
displays the plot of the ratios of the carbon dioxide to 
oxygen in combination with a plot of the previously mea-
sured ratios of carbon dioxide to oxygen in normal and 
afflicted subjects. 
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19. A method of diagnosing the presence of abnormal 
respiratory function, said method comprising: 
providing a patient with a device adapted for measuring 
inspired and expired carbon dioxide and oxygen and 
flow rate; 'measuring the flow rate and partial pressures 
of carbon dioxide and oxygen in tidal breaths over a 
predetermined time period; 
computing the ratio of carbon dioxide to oxygen in 
real-time; 
visually plotting the computed ratios of carbon dioxide to 
oxygen; and 
determining the presence of abnormal respiratory func-
tion based on the slope of predetermined portions of the 
plot of the computed ratios of carbon dioxide to oxy-
gen. 
20. The method of claim 19, wherein the ratio of carbon 
dioxide to oxygen is plotted as a function of volume. 
21. The method of claim 19, wherein the ratio of carbon 
dioxide to oxygen is plotted as a function of time. 
22. The method of claim 19, wherein the step of deter-
mining the presence of abnormal respiratory function 
includes comparing the slope of predetermined portions of 
the plot of the computed ratios of carbon dioxide to oxygen 
to the slope of predetermined portions of the plot of the 
ratios of carbon dioxide to oxygen in normal and afflicted 
subjects. 
23. A method of diagnosing the presence of abnormal 
respiratory function, said method comprising: 
providing a patient with a device adapted for measuring 
inspired and expired carbon dioxide and oxygen and 
flow rate; 
measuring inspired and expired carbon dioxide and oxy-
gen and flow rate; 
determining the start of inspiration and the start of expi-
ration based upon predetermined absolute thresholds 
and the measured flow rates; 
calculating the average inspiration time and expiration 
time over a predetermined period of time; 
calculating the ratio of the average inspiratory time 
divided by the expiratory time over the predetermined 
period of time; and 
displaying the calculated ratio of the average inspiratory 
time divided by the expiratory time over the predeter-
mined period of time. 
24. The method of claim 23, further comprising the step 
of displaying the calculated ratio of the average inspiratory 
time divided by the expiratory time in combination with 
previously measured ratios of average inspiratory time 
divided by the expiratory time in normal and afflicted 
subjects. 
25. The method of claim 23, further comprising the step 
of determining the presence of an airways obstruction based 
on the difference between the calculated ratio of the average 
inspiratory time divided by the expiratory time and the 
previously measured ratios of average inspiratory time 
divided by the expiratory time in normal and afflicted 
subjects. 
* * * * * 
